PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...

2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, ...

PTC Inc. ( (PTC) ) has released its Q4 earnings. Here is a breakdown of the information PTC Inc. presented to its investors. PTC Inc. is a ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

PTC Inc. PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share.

Fiscal '25 Constant Currency ARR Growth Guidance: 9% to 10%. PTC Inc (NASDAQ:PTC) reported a solid 25% year-over-year growth in free cash flow for fiscal 2024. The company achieved a 12% year-over ...

Q4 2024 Earnings Conference Call November 6, 2024 5:00 PM ETCompany ParticipantsMatt Shimao - Head of Investor RelationsNeil Barua ...

International Assets Investment Management LLC grew its stake in shares of PTC Inc. (NASDAQ:PTC – Free Report) by 786.5% during the third quarter, Holdings Channel reports. The institutional investor ...

PTC Inc. (PTC) revealed a profit for its fourth quarter that increased from last year and beat the Street estimates. The company's ...

BOSTON (AP) — BOSTON (AP) — PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share.